A citation-based method for searching scientific literature

Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
Times Cited: 776



Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias, Deolinda Pereira, Pauline Wimberger, Ana Oaknin, Mansoor Raza Mirza, Philippe Follana, David Bollag, Isabelle Ray-Coquard. J Clin Oncol 2014
Times Cited: 752




List of shared articles



Times cited

A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer.
Yoshiko Nanki, Hiroyuki Nomura, Naomi Iwasa, Keiko Saotome, Ai Dozen, Tomoko Yoshihama, Takuro Hirano, Shiho Hashimoto, Tatsuyuki Chiyoda, Wataru Yamagami,[...]. Jpn J Clin Oncol 2021
1

The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer.
Katrine Wallace, Kelly Adamski, Ashwini Pai, Darya Rose, Anita Chawla. Pharmacoeconomics 2021
0

Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gynecological Society of Kinki district, Japan.
Seiji Mabuchi, Misa Yamamoto, Hiroko Murata, Takuya Yokoe, Junzo Hamanishi, Yoshito Terai, Hikaru Imatake, Yasushi Mabuchi, Taisuke Mori, Fuminori Kitada,[...]. Int J Clin Oncol 2021
1

Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
Vinaya Gogineni, Susan Morand, Hannah Staats, Rachel Royfman, Monika Devanaboyina, Katelyn Einloth, Danielle Dever, Laura Stanbery, Phylicia Aaron, Luisa Manning,[...]. J Cancer 2021
2

SEOM clinical guideline in ovarian cancer (2020).
A Redondo, E Guerra, L Manso, C Martin-Lorente, J Martinez-Garcia, J A Perez-Fidalgo, M Q Varela, M J Rubio, M P Barretina-Ginesta, A Gonzalez-Martin. Clin Transl Oncol 2021
1

The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
Shiru Liu, Lawrence Kasherman, Rouhi Fazelzad, Lisa Wang, Genevieve Bouchard-Fortier, Stephanie Lheureux, Monika K Krzyzanowska. Gynecol Oncol 2021
1

Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer.
Virginie Mieulet, Camille Garnier, Yann Kieffer, Thomas Guilbert, Fariba Nemati, Elisabetta Marangoni, Gilles Renault, Foucauld Chamming's, Anne Vincent-Salomon, Fatima Mechta-Grigoriou. Sci Rep 2021
2

REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Katrin M Sjoquist, David Espinoza, Linda Mileshkin, Sumitra Ananda, Catherine Shannon, Sonia Yip, Jeffrey Goh, David Bowtell, Michelle Harrison, Michael L Friedlander. Gynecol Oncol 2021
2

The systemic treatment of recurrent ovarian cancer revisited.
T Baert, A Ferrero, J Sehouli, D M O'Donnell, A González-Martín, F Joly, J van der Velden, P Blecharz, D S P Tan, D Querleu,[...]. Ann Oncol 2021
2

The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.
Amy Loreen, Clarissa Polen-De, Bradley J Monk, Amanda L Jackson, Caroline C Billingsley, Thomas J Herzog. Gynecol Oncol 2021
0

Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer.
Olivia Le Saux, Hélène Vanacker, Fatma Guermazi, Mélodie Carbonnaux, Clémence Roméo, Louis Larrouquère, Olivier Trédan, Isabelle Ray-Coquard. Future Oncol 2021
0

Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
Rodney P Rocconi, Erin E Stevens, Justin N Bottsford-Miller, Sharad A Ghamande, Jeffrey Elder, Leslie L DeMars, Adnan Munkarah, Phylicia Aaron, Laura Stanbery, Gladice Wallraven,[...]. Cancer Gene Ther 2021
0

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors.
Camilla Nero, Francesca Ciccarone, Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Vanda Salutari, Maria Vittoria Carbone, Giovanni Scambia, Domenica Lorusso. Cancers (Basel) 2021
0

PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience.
Amit Agarwal, Saphalta Baghmar, Chandragouda Dodagoudar, Suhail Qureshi, Aseem Khurana, Vikas Vaibhav, Guresh Kumar. JCO Glob Oncol 2021
0

Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review.
Melissa Bradbury, Eva Borràs, Assumpció Pérez-Benavente, Antonio Gil-Moreno, Anna Santamaria, Eduard Sabidó. Cancers (Basel) 2021
0

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria,[...]. Int J Gynecol Cancer 2021
1

A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
Mitsuya Ishikawa, Taro Shibata, Takashi Iwata, Shin Nishio, Toshio Takada, Shiro Suzuki, Koji Horie, Wataru Kudaka, Masahiro Kagabu, Michihiro Tanikawa,[...]. Gynecol Oncol 2021
1

The impact of body composition on treatment in ovarian cancer: a current insight.
Veronica McSharry, Kate Glennon, Amy Mullee, Donal Brennan. Expert Rev Clin Pharmacol 2021
0

The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment.
Mark A Eckert, Carlos Orozco, Jason Xiao, Melissa Javellana, Ernst Lengyel. Cancers (Basel) 2021
0

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma.
Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Yuki Shiko, Yoshihito Ozawa, Yohei Kawasaki, Makio Shozu. Cancers (Basel) 2021
0


The use of bevacizumab is correlated with improved post-progression survival in advanced recurrent ovarian cancer.
Shintaro Yanazume, Takashi Ushiwaka, Mika Fukuda, Shinichi Togami, Masaki Kamio, Hiroaki Kobayashi. Jpn J Clin Oncol 2021
0

Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.
K E Broekman, M van Kruchten, H van Tinteren, C Sessa, M Jalving, A K L Reyners. ESMO Open 2021
0


Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.
Bahar Yetkin-Arik, Arnoud W Kastelein, Ingeborg Klaassen, Charlotte H J R Jansen, Yani P Latul, Miloš Vittori, Aydan Biri, Korhan Kahraman, Arjan W Griffioen, Frederic Amant,[...]. Biochim Biophys Acta Rev Cancer 2021
5

Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Katherine C Kurnit, Gini F Fleming, Ernst Lengyel. Obstet Gynecol 2021
4

Oregovomab: an investigational agent for the treatment of advanced ovarian cancer.
Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Camilla Nero, Francesca Ciccarone, Domenica Lorusso, Anna Fagotti, Giovanni Scambia. Expert Opin Investig Drugs 2021
0

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Sandro Pignata, Domenica Lorusso, Florence Joly, Ciro Gallo, Nicoletta Colombo, Cristiana Sessa, Aristotelis Bamias, Vanda Salutari, Frédèric Selle, Simona Frezzini,[...]. Lancet Oncol 2021
7

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
J A Ledermann, A C Embleton-Thirsk, T J Perren, G C Jayson, G J S Rustin, S B Kaye, H Hirte, A Oza, M Vaughan, M Friedlander,[...]. ESMO Open 2021
1

Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
Megan E Buechel, Danielle Enserro, Robert A Burger, Mark F Brady, Katrina Wade, Angeles Alvarez Secord, Andrew B Nixon, Seyedehnafiseh Mirniaharikandehei, Hong Liu, Bin Zheng,[...]. Gynecol Oncol 2021
0

Bevacizumab in advanced endometrial cancer.
Maria M Rubinstein, Shannan Dickinson, Priyanka Narayan, Qin Zhou, Alexia Iasonos, Weining Ma, Yulia Lakhman, Vicky Makker. Gynecol Oncol 2021
1

Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
Yufei Yang, Lingfang Xia, Yong Wu, Hongyu Zhou, Xin Chen, Haoran Li, Midie Xu, Zihao Qi, Ziliang Wang, Huizhen Sun,[...]. Cancer Commun (Lond) 2021
5

Management of advanced ovarian cancer in Spain: an expert Delphi consensus.
Andres Redondo, Ana Oaknin, Maria Jesus Rubio, Maria-Pilar Barretina-Ginesta, Ana de Juan, Luis Manso, Ignacio Romero, Cristina Martin-Lorente, Andres Poveda, Antonio Gonzalez-Martin. J Ovarian Res 2021
0

Recent advancements of antiangiogenic combination therapies in ovarian cancer.
Daniel An, Susana Banerjee, Jung-Min Lee. Cancer Treat Rev 2021
0

A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA.
Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys. Acta Clin Belg 2021
0

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
Isabelle Ray-Coquard, David Cibula, Mansoor R Mirza, Alexander Reuss, Caterina Ricci, Nicoletta Colombo, Horst Koch, Frédéric Goffin, Antonio González-Martin, Petronella B Ottevanger,[...]. Int J Cancer 2020
8

Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer.
Ezgi Guler, Daniel A Smith, Bhanusupriya Somarouthu, Rahul Gujrathi, Nikhil H Ramaiya, Sree Harsha Tirumani. Abdom Radiol (NY) 2020
2

Current Development of Monoclonal Antibodies in Cancer Therapy.
Sagun Parakh, Dylan King, Hui K Gan, Andrew M Scott. Recent Results Cancer Res 2020
5

Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Ling Wang, Qi Wang, Yangchun Xu, Manhua Cui, Liying Han. Curr Drug Targets 2020
5

Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening.
Quan Guo, Qing Yang, Jun Li, Guipeng Liu, Igor Nikoulin, Steve Jia. Anticancer Drugs 2020
3

Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Carolyn E Haunschild, Krishnansu S Tewari. Future Oncol 2020
7

Personalized Medicine in Gynecologic Cancer: Fact or Fiction?
Logan Corey, Ana Valente, Katrina Wade. Surg Oncol Clin N Am 2020
1

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B Sibley, Yingmiao Liu, Mark D Starr, J Chris Brady, Heather A Lankes, Herbert I Hurwitz,[...]. Clin Cancer Res 2020
9

Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Robert D Morgan, Susana Banerjee, Marcia Hall, Andrew R Clamp, Cong Zhou, Jurjees Hasan, Cecilia Orbegoso, Sarah Taylor, Jonathan Tugwood, Alexander R Lyon,[...]. Gynecol Oncol 2020
1

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Robert L Coleman, Katelyn F Handley, Robert Burger, Graziela Zibetti Dal Molin, Robert Stagg, Anil K Sood, Kathleen N Moore. Gynecol Oncol 2020
8

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
David M O'Malley, Ursula A Matulonis, Michael J Birrer, Cesar M Castro, Lucy Gilbert, Ignace Vergote, Lainie P Martin, Gina M Mantia-Smaldone, Antonio González Martin, Raquel Bratos,[...]. Gynecol Oncol 2020
21

[Current advances in immunotherapy in ovarian cancer].
Olivia Le Saux, Bertrand Dubois, Marc-Henri Stern, Magali Terme, Eric Tartour, Jean-Marc Classe, Nicolas Chopin, Olivier Trédan, Christophe Caux, Isabelle Ray-Coquard. Bull Cancer 2020
3


Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Josep Garcia, Herbert I Hurwitz, Alan B Sandler, David Miles, Robert L Coleman, Regula Deurloo, Olivier L Chinot. Cancer Treat Rev 2020
101

Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?
Joanna Glajzer, Jacek P Grabowski, Jalid Sehouli, Jacobus Pfisterer. Curr Treat Options Oncol 2020
1